Navidea Biopharmaceuticals Inc Quick ratio

Quel est le Quick ratio de Navidea Biopharmaceuticals Inc?

Le Quick ratio de Navidea Biopharmaceuticals Inc est 0.79

Quelle est la définition de Quick ratio?



«Quick ratio» est le ratio de liquidité qui mesure la capacité d'une entreprise à utiliser ses actifs rapides pour faire face à ses obligations à court terme immédiatement.

The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.

Quick ratio des entreprises dans Health Care secteur sur NYSEMKT par rapport à Navidea Biopharmaceuticals Inc

Que fait Navidea Biopharmaceuticals Inc?

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de

Entreprises avec quick ratio similaire à Navidea Biopharmaceuticals Inc